Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEZS-108 in Advanced Urothelial Carcinoma
NCT01234519Phase 2Terminated
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Nov 2010
- Primary completion
- Nov 2014
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoptarelin doxorubicin in urothelial carcinoma (UC) (5 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoint: Maximum Tolerated Dose. Started Nov 2010; status: terminated.
02
Drugs
zoptarelin doxorubicin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01234519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234519.